# Imbria Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imbria-pharmaceuticals

- Industry: Healthcare IT
- Headquarters: Boston, US
- Website: imbria.com
- Total disclosed funding: $59M
- Latest round: Series B (Mar 10, 2025)
- Investors on record: 6

## About

Imbria Pharmaceuticals is focused on developing innovative therapies for cardiometabolic disorders, particularly targeting conditions like non-obstructive hypertrophic cardiomyopathy and heart failure. The company aims to enhance treatment outcomes for patients through advanced drug development.

Imbria Pharmaceuticals, Inc. is dedicated to the development of novel treatments for cardiometabolic disorders. Founded in 2018 in Boston, US, the company has engaged in one significant deal to date. In March 2025, Imbria Pharmaceuticals, Inc. raised USD 59.20 million in series B funding led by new investor Deep Track Capital, with participation from other new investors AN Ventures, Catalio Capital Management, and Cytokinetics, Inc. Returning investors RA Capital Management, SV Health Investors, and other unspecified investors also participated in the round. As of May 2025, Alvin Shih is the Chief Executive Officer (CEO) of the company.

Imbria Pharmaceuticals specializes in developing novel therapies aimed at treating cardiometabolic disorders, specifically focusing on conditions such as non-obstructive hypertrophic cardiomyopathy (HCM), stable angina, and heart failure with preserved ejection fraction (HFpEF). Their core product, Ninerafaxstat, is designed to optimize cellular energy metabolism in the heart, addressing the underlying pathophysiology of these conditions. By leveraging their understanding of cellular metabolism, Imbria seeks to provide new treatment options for patients who face limited or inadequate therapies. The primary target demographic includes patients suffering from HCM, stable angina, and HFpEF, which collectively impact a significant portion of the adult population globally. Imbria's products are aimed at markets primarily in North America and Europe, where there is a recognized need for advanced treatment modalities in cardiometabolic health.

Imbria Pharmaceuticals generates revenue through strategic partnerships and collaborations in the pharmaceutical landscape, particularly through clinical trials and product development agreements for their lead candidate, Ninerafaxstat. The business model may involve licensing agreements with larger pharmaceutical firms, who may seek to co-develop or commercialize these innovative therapies. Transactions typically occur through structured agreements that outline milestones, including upfront payments and potential royalties based on the successful commercialization of their products. As clinical data shows promising results, especially from trials like the IMPROVE-DiCE and IMPROVE-HCM studies, Imbria positions itself to attract increasing investor and partnership interest, enhancing its revenue potential as it moves closer to market entry with its flagship product.

The company plans to utilize the March 2025 funding to launch FORTITUDE-HCM, a Phase 2b randomized, double-blind, placebo-controlled clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM), in Q2 2025, with topline data in late 2026.

## Funding rounds

- Series B, Mar 10, 2025, $59M — SV Health Investors, RA Capital Management, Cytokinetics, Inc., Catalio Capital Management, Deep Track Capital, AN Ventures

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Cytokinetics, Inc. — Series B
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B
- AN Ventures (https://capitalatlas.ai/funds/an-ventures) — Series B